Digital Endpoint Development for Alzheimer's Disease: The Importance of Patients as Partners, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn about how patient engagement can enhance digital endpoint development in Alzheimer's disease clinical trials. The featured speakers include stakeholders representing the perspectives of pharma, technology developers, and most importantly, patients. The panel will discuss different approaches to patient engagement in digital health. The webinar will close with a discussion between stakeholders focused on opportunities for promoting patient centricity in Alzheimer's disease drug development and identify areas for improvement.

TORONTO, May 3, 2023 /PRNewswire-PRWeb/ -- Digital health technologies (DHTs) like smartphones and wearable sensors hold great promise to advance drug development and discovery in neurodegenerative diseases, particularly Alzheimer's disease. Through objective, continuous, remote capture of real-world outcomes, DHTs have the capacity to measure the impact of novel treatments on how patients with Alzheimer's disease feel and function in their real-world environments, which, in turn, enables the development of drugs that improve aspects of health that matter most to patients. A digital endpoint derived from DHTs thus gives deeper insight on a patient's health.

To ensure the development of patient-centric endpoints in Alzheimer's disease drug development, engaging patients as partners throughout the process of digital endpoint development is critical. In this webinar, the featured speakers bring together stakeholders representing the perspectives of pharma, technology developers, and most importantly, patients. The panel will discuss different approaches to patient engagement in digital health.

This webinar will close with a discussion between stakeholders focused on opportunities for promoting patient centricity in Alzheimer's disease drug development and identify areas for improvement.

Register for this webinar today to understand how patient engagement can enhance digital endpoint development in Alzheimer's disease clinical trials.

Join Jen Blankenship (Moderator), Senior Research Scientist, VivoSense; Shelby Bachman, Research Scientist, VivoSense; Jelena Curcic, Associate Director & Senior Principal Data Scientist, Novartis Institutes for Biomedical Research (NIBR)/Biomarker Development; Francesca Cormac, Chief Scientist, Cambridge Cognition; and Michael Ellenbogen, International Dementia Advocate & Connecter, for the live webinar on Tuesday, May 23, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Digital Endpoint Development for Alzheimer's Disease: The Importance of Patients as Partners.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]

SOURCE Xtalks